- 2022.9.8
- News Release CAGE Bio, TAGCyx and PeptiStar announce execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
- 2022.3.23
- News Release TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).
- 2021.7.7
- News Release TAGCyx raises approximately 210 million JPY
- 2021.3.22
- News Release Prof. Shinsuke Sando at THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®
- 2021.3.5
- News Release TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
- 2021.2.19
- News Release Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®
- 2020.11.25
- News Release SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY
- 2020.11.17
- News Release Showa Denko Materials and the Drug Development Startup TAGCyx Sign a Commissioned Development Agreement on Regenerative Medicine Technologies
- 2020.9.18
- News Release TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases.
- 2020.5.5
- News Release TAGCyx raises approximately 200 million JPY
- 2020.2.19
- News Release TAGCyx and GC Pharma has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004
- 2019.12.25
- News Release TAGCyx receives milestone payment for collaborative research with HEALIOS K.K.
12